A Study of LY573636-Sodium in the Treatment of Patients With Metastatic Soft Tissue Sarcoma

• Status: Completed
• Trial end date: 2010-02-01
• Target enrollment: 0
• Participant gender: All

Summary

The primary purpose of the study is to estimate the time from the first dose of LY573636-sodium (hereafter referred to as LY573636) to the date your physician determines that your disease has progressed or worsened.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Eli Lilly and Company

Criteria

Inclusion Criteria:

• Diagnosis of soft tissue sarcoma that is unresectable or metastatic

• Have received one or two (but no more than two) prior treatment regimens for metastatic soft tissue sarcoma, one of which must have included doxorubicin (adriamycin).

• Must have stopped all previous treatments for cancer, including chemotherapy, radiation therapy or other investigational treatments for cancer for at least 30 days

Exclusion Criteria:

• Participants with primary bone sarcoma (for example osteosarcoma, Ewing's sarcoma, chondrosarcoma), gastrointestinal stromal tumor (GIST) and Kaposi's sarcoma

• Serious pre-existing medical problems (as determined by your doctor)

• Have received more than two previous systemic treatment regimens for unresectable or metastatic soft tissue sarcoma

• Have a second primary cancer (unless cancer-free for more than 2 years)

• Active treatment with Warfarin (Coumadin)